Advisor Partners LLC decreased its stake in Hologic, Inc. (NASDAQ:HOLX) by 0.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,682 shares of the medical equipment provider’s stock after selling 43 shares during the period. Advisor Partners LLC’s holdings in Hologic were worth $212,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Russell Investments Group Ltd. raised its position in Hologic by 229.7% in the second quarter. Russell Investments Group Ltd. now owns 1,059,586 shares of the medical equipment provider’s stock valued at $48,100,000 after buying an additional 738,215 shares during the last quarter. Earnest Partners LLC raised its position in Hologic by 168,145.9% in the first quarter. Earnest Partners LLC now owns 205,260 shares of the medical equipment provider’s stock valued at $8,734,000 after buying an additional 205,138 shares during the last quarter. Teachers Advisors LLC raised its position in Hologic by 36.4% in the first quarter. Teachers Advisors LLC now owns 877,549 shares of the medical equipment provider’s stock valued at $37,340,000 after buying an additional 234,002 shares during the last quarter. Swiss National Bank raised its position in Hologic by 23.4% in the first quarter. Swiss National Bank now owns 1,028,124 shares of the medical equipment provider’s stock valued at $43,747,000 after buying an additional 195,100 shares during the last quarter. Finally, Aperio Group LLC raised its position in Hologic by 5.0% in the second quarter. Aperio Group LLC now owns 82,449 shares of the medical equipment provider’s stock valued at $3,742,000 after buying an additional 3,914 shares during the last quarter. 94.46% of the stock is owned by institutional investors.

Shares of Hologic, Inc. (NASDAQ HOLX) opened at 38.20 on Friday. Hologic, Inc. has a 12-month low of $35.15 and a 12-month high of $46.80. The company has a market capitalization of $10.71 billion, a P/E ratio of 14.23 and a beta of 0.90. The company has a 50 day moving average price of $43.73 and a 200 day moving average price of $42.89.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.01. The business had revenue of $806.10 million during the quarter, compared to analysts’ expectations of $799.70 million. Hologic had a return on equity of 23.18% and a net margin of 25.65%. The company’s revenue was up 12.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.51 EPS. Equities analysts anticipate that Hologic, Inc. will post $2.01 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This news story was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://www.watchlistnews.com/hologic-inc-nasdaqholx-stake-cut-by-advisor-partners-llc/1481008.html.

HOLX has been the subject of several recent analyst reports. Royal Bank Of Canada dropped their price objective on shares of Hologic from $50.00 to $45.00 and set a “sector perform” rating for the company in a research note on Thursday, August 3rd. BidaskClub lowered shares of Hologic from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. Zacks Investment Research raised shares of Hologic from a “sell” rating to a “hold” rating in a research note on Friday, August 4th. Canaccord Genuity reissued a “buy” rating and set a $53.00 target price on shares of Hologic in a research note on Tuesday, May 9th. Finally, Barclays PLC lowered their target price on shares of Hologic from $53.00 to $51.00 and set an “overweight” rating for the company in a research note on Thursday, August 3rd. One analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have assigned a buy rating to the stock. Hologic currently has a consensus rating of “Buy” and an average target price of $48.64.

In related news, insider Peter J. Valenti III sold 10,005 shares of the firm’s stock in a transaction dated Tuesday, May 30th. The stock was sold at an average price of $43.44, for a total transaction of $434,617.20. Following the completion of the transaction, the insider now directly owns 20,994 shares in the company, valued at approximately $911,979.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Elaine Ullian sold 6,902 shares of the firm’s stock in a transaction dated Thursday, August 3rd. The shares were sold at an average price of $40.12, for a total value of $276,908.24. Following the transaction, the director now owns 23,810 shares of the company’s stock, valued at $955,257.20. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 60,627 shares of company stock valued at $2,632,911. Company insiders own 0.79% of the company’s stock.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.